With high expression levels of PDL-1 and EGFR on the cell surface plus both BRAF V600E and KRAS G13D existing within its genome, the A375 KRAS G13D mutant isogenic line is an ideal model suited for future studies focused on the tumor microenvironment and integrated combination therapy strategies. Here, KRAS is linked to neoplasm.